{
    "clinical_study": {
        "@rank": "136259", 
        "acronym": "PPI", 
        "arm_group": [
            {
                "arm_group_label": "Proton Pump Inhibitor", 
                "arm_group_type": "Experimental", 
                "description": "Lansoprazole (Prevacid)"
            }, 
            {
                "arm_group_label": "Vitamin pill", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In this randomized controlled crossover study, the investigators propose to test the\n      hypothesis that proton pump inhibitors (PPIs) increase plasma levels of asymmetric\n      dimethylarginine (ADMA), which is a marker of endothelial dysfunction. The authors propose\n      to evaluate ADMA concentrations and vascular function analysis in healthy volunteers and\n      adults with a history of cardiovascular disease given PPI vs placebo for four weeks each."
        }, 
        "brief_title": "Effect of Proton Pump Inhibitors on Endothelial Function", 
        "condition": "Endothelial Dysfunction", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female volunteers aged 18 to 75 years (n=10) or male or female\n             volunteers with a history of coronary or peripheral artery disease (n=10)\n\n          -  Able to understand the nature of the study and to give written informed consent\n\n          -  Able to communicate well with the investigator himself or his/her representatives\n\n          -  Body Mass Index between 18 kg/m^2 and 35 kg/m^2 at the screening visit\n\n          -  Creatinine <1.5, and liver enzymes <2x normal, with all laboratory tests considered\n             normal or of no significant clinical relevance to the study by the investigator\n\n        Exclusion Criteria:\n\n          -  Contra-indication to proton pump inhibitor treatment\n\n          -  Current treatment with PPI or H2 antagonist, and not able to tolerate withdrawal or\n             washout of medication.\n\n          -  Current or historical evidence of clinically severe cardiovascular, neurological,\n             hematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological,\n             metabolic or psychiatric disease.\n\n          -  Any other acute or chronic disease which could influence the volunteer's health\n             and/or the study results\n\n          -  Presence or history of malabsorption or any gastrointestinal surgery except\n             appendectomy or hernia repair\n\n          -  Use of enzyme inducers or enzyme inhibitor drugs within the last three months before\n             the first drug administration\n\n          -  Participation in another ongoing clinical trial\n\n          -  Past or current drug exposure amounting to drug abuse or addiction\n\n          -  Past or current alcohol exposure amounting to alcohol abuse or addiction (i.e. > 28\n             units per week for males, where 1 unit = one measure of spirit (25 mL), one glass of\n             wine (125 mL) or 1/2 pint beer)\n\n          -  Donation of blood or any other major blood loss (>500 mL) within three months before\n             the study\n\n          -  Unwilling or unable to comply with the study protocol for any reason or in the\n             opinion of the investigator should not participate in the study\n\n          -  Positive test for hepatitis B surface antigen, hepatitis C antibody, HIV-1 or HIV-2\n             antibody at screening\n\n          -  Known allergy or intolerance to any other compound in the study drug or any other\n             closely related compound"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022280", 
            "org_study_id": "23848", 
            "secondary_id": "1144447-121-DHAXB"
        }, 
        "intervention": {
            "arm_group_label": "Proton Pump Inhibitor", 
            "intervention_name": "Lansoprazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Lansoprazole", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "contact": {
                "email": "fouziak@stanford.edu", 
                "last_name": "Fouzia Khan", 
                "phone": "650-736-1410"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University"
            }, 
            "investigator": {
                "last_name": "Nicholas Leeper, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA.", 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Nicholas Leeper, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in reactive hyperemia index as measured by peripheral arterial tonometry (EndoPAT)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 1 week, 5 weeks, 7 weeks, 11 weeks, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022280"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in blood ADMA level", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 1 week, 5 weeks, 7 weeks, 11 weeks, 12 weeks"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}